Stryker (NYSE:SYK) Stock Unloaded Rep. Thomas H. Kean, Jr.

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Corporation (NYSE:SYK). In a filing disclosed on December 19th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on November 20th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/26/2025.
• Sold $15,001 – $50,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/20/2025.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 9/25/2025.

Stryker Stock Up 0.6%

Shares of SYK opened at $355.21 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $365.26 and a two-hundred day moving average price of $377.49. The stock has a market cap of $135.84 billion, a price-to-earnings ratio of 46.68, a P/E/G ratio of 2.51 and a beta of 0.89. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Citigroup decreased their price objective on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Rothschild & Co Redburn began coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Finally, Truist Financial dropped their price target on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $431.84.

Insiders Place Their Bets

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 522,118 shares of company stock worth $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in Stryker in the second quarter valued at approximately $1,882,173,000. Alliancebernstein L.P. grew its holdings in shares of Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after buying an additional 4,223,366 shares during the period. Corient Private Wealth LLC increased its position in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Finally, Strive Asset Management LLC acquired a new stake in Stryker during the 3rd quarter worth $227,389,000. Institutional investors own 77.09% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.